Halim Charbel, MD
Gastroenterology · Germantown, MDNPI 1740431501
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $67,350 of the $88,449 with a category attached, or 76.1%. Boston Scientific accounts for 85.2% of it on its own, with 34 other manufacturers making up the rest. 2025 is the largest year on record at $74,176, more than ten times the $4,800 reported in 2019. Among gastroenterology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 400 payments — averaging $221.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$75K
- Apollo Endosurgery US Inc$5K
- AbbVie$4K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$718
- Johnson & Johnson$587
- Ardelyx, Inc.$340
- plus $3K from 29 others
What the payments were for
- Consulting fees$3,8004%
- Speaking & faculty fees$67,35076%
- Travel & lodging$7,1638%
- Food & beverage$10,09611%
- Education$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 83 | $75,333 |
| Apollo Endosurgery US Inc | 29 | $4,636 |
| AbbVie(2 entities) | 68 | $3,987 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 45 | $718 |
| Johnson & Johnson(2 entities) | 26 | $587 |
| Ardelyx, Inc. | 12 | $340 |
| Novo Nordisk | 16 | $320 |
| QOL Medical, LLC | 14 | $285 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $205 |
| Gilead | 10 | $204 |
| Ironwood Pharmaceuticals, Inc | 11 | $198 |
| Bristol Myers Squibb | 13 | $192 |
| Sanofi | 7 | $159 |
| Trevena, Inc. | 6 | $132 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Lilly USA, LLC | 5 | $117 |
| Regeneron Healthcare Solutions, Inc. | 6 | $107 |
| Redhill Biopharma Inc. | 6 | $100 |
| Braintree Laboratories, Inc. | 6 | $98 |
| Madrigal Pharmaceuticals | 3 | $97 |
| Intercept Pharmaceuticals, Inc. | 3 | $68 |
| Merck | 3 | $66 |
| Phathom Pharmaceuticals, Inc. | 5 | $60 |
| Nestle Healthcare Nutrition Inc. | 4 | $58 |
| Foundation Medicine, Inc. | 1 | $47 |
| Endogastric Solutions, Inc | 1 | $31 |
| Ambu Inc. | 1 | $27 |
| Pfizer | 1 | $25 |
| Digestive Care, Inc. | 1 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Olympus America Inc. | 1 | $16 |
| UCB, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OverStitch Endoscopic Suturing System$28,580
- ORBERA Intragastric Balloon System$23,471
- GENERAL - THERAPIES$17,629
- APOLLO ESG System$5,598
- Apollo ESG NXT System$1,605
- LINZESS$1,400
- VIBERZI$1,320
- Orbera$793
- Overstitch$624
- X-Tack Endoscopic HeliX Tacking System$214
- APOLLO Revise System$171
- STELARA$125
- Entyvio$115
- SPYGLASS$111
How this compares
$88,449 in reported general payments places this provider in the 95th percentile of 455 gastroenterology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 30 | $29,697 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 11 | $1,769 |
| Dicyclomine Hcl | 21 | $626 |
| Pantoprazole Sodium | 25 | $469 |
| Omeprazole | 34 | $392 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $3,987 | $29,69730 claims |
| Braintree Laboratories, Inc.Sutab | $98 | $1,76911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 455 gastroenterology providers in Maryland.
Other gastroenterology in Germantown
- Apurva ModiRockville$1.1M
- Sergey KantsevoyBaltimore$1.1M
- Anurag MaheshwariBaltimore$803K
- Aline Charabaty PishvaianBaltimore$631K
- Zachary BormanChevy Chase$520K
- Mouen KhashabBaltimore$440K
- Erica CohenChevy Chase$385K
- Natarajan RavendhranCatonsville$367K
- Raymond CrossBaltimore$341K
- Raja TaunkAnnapolis$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.